Latest Biota Holdings Limited Stories

NEW YORK, Sept. 12, 2012 /PRNewswire/ -- The Mangrove Partners Fund, L.P. ("Mangrove Partners"), one of the largest stockholders of Nabi Biopharmaceuticals (NasdaqGS: NABI), announced today that both Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have recommended that stockholders support Mangrove Partners and vote against the proposed merger (the "Transaction") of Nabi with Biota Holdings Limited (BTA.AX). Both preeminent proxy advisory firms...

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- The Mangrove Partners Fund, L.P., one of Nabi Biopharmaceuticals' largest stockholders, today announced that it has delivered a letter to the stockholders of Nabi Biopharmaceuticals (Nasdaq: NABI). The full text of the letter follows: August 16, 2012 Dear Fellow Stockholders: Your support in voting against the proposed merger (the "Transaction") between Nabi Biopharmaceuticals ("Nabi" or the "Company") and Biota Holdings Limited,...

Biota Holdings Limited (ASX: BTA) today announced that its second generation, influenza treatment, CS-8958, has successfully completed its initial Phase II clinical evaluation, showing favourable outcomes against all measured endpoints. The initial Phase III trial is scheduled to commence later this year. CS-8958 is a long acting neuraminidase inhibitor (LANI), and is co-owned with Daiichi-Sankyo. The Phase II clinical trial was designed to test the safety and efficacy of CS-8958 in several...

Biota Holdings Limited (ASX: BTA) today announced it had concluded its litigation against GlaxoSmithKline (GSK). The announcement followed formal mediation between by the parties ordered by the Victorian Supreme Court. The mediation provided the parties with the opportunity to resolve their differences and eliminate the uncertainty and costs associated with the legal process. Biota and GSK have agreed to normalise their relationship to pursue the best interests of Relenza, with senior...